A Look At JD Health International’s Valuation After Analyst Optimism And Strong Quarterly Earnings

JD Health International (SEHK:6618) has drawn fresh attention after favorable analyst commentary coincided with quarterly results showing year-on-year revenue and profit growth, prompting investors to reassess the online healthcare platform’s recent share performance. See our latest analysis for JD Health International. The recent 5.01% 1 day share price return and 15.21% 7 day share price return suggest momentum has picked up again, although the 143.38% 1 year total shareholder return contrasts with flat 3 year and weaker 5 year total shareholder returns. This hints at a story that is still rebuilding rather than fully reset. If JD Health’s move has you looking across the sector, this could be a useful moment to scan other healthcare stocks that might fit a similar online or services driven healthcare theme. With JD Health trading at HK$67.05 alongside an intrinsic value estimate and analyst targets that sit higher, the real question is whether this signals an undervalued online healthcare platform or a market that is already pricing in future growth. Most Popular Narrative: 12.7% Undervalued With JD Health last closing at HK$67.05 against a narrative fair value of about HK$76.81, the gap comes down to growth, margins and future earnings multiples. Analysts are assuming JD Health International's revenue will grow by 14.7% annually over the next 3 years. In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 34.4x on those 2028 earnings, down from 39.6x today. Read the complete narrative. Curious how steady revenue growth, modest margin shifts and a premium future P/E all tie together into that higher fair value estimate? The full narrative lays out the earnings path, the expected share count changes and the discount rate that hold this valuation story together. Result: Fair Value of HK$76.81 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this narrative could be shaken if competition squeezes margins or if heavier AI and omnichannel investment does not convert into the expected earnings profile. Find out about the key risks to this JD Health International narrative. Another View: What The P/E Ratio Is Telling You While the fair value narrative points to JD Health looking undervalued, the current 40.8x P/E tells a more mixed story. It sits well above the Asian Consumer Retailing average of 17x and the 21.5x fair ratio, yet below peers at 76.2x. This suggests both potential upside and valuation risk tied to expectations staying high. See what the numbers say about this price — find out in our valuation breakdown. SEHK:6618 P/E Ratio as at Jan 2026 Build Your Own JD Health International Narrative If you see the numbers differently or prefer to test your own assumptions, you can build a custom JD Health view in minutes with Do it your way. A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding JD Health International. Looking for more investment ideas? If JD Health has sharpened your interest, do not stop here. This is your chance to broaden your watchlist with a few focused stock idea shortlists. Spot potential value opportunities early by scanning these 885 undervalued stocks based on cash flows that the market might be pricing differently to their underlying cash flows. Ride major technology shifts by checking out these 26 AI penny stocks shaping how artificial intelligence filters into real businesses. Boost your income focus by reviewing these 12 dividend stocks with yields > 3% that combine yield above 3% with listed fundamentals. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.